Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab) dosing follows fixed intervals for most approved indications, with no routine adjustments based on weight, age, or blood levels. Adults with plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis typically start with 300 mg subcutaneous injection at weeks 0, 1, 2, 3, then every 4 weeks. For hidradenitis suppurativa, it's 300 mg weekly for the first 4 weeks, then every 4 weeks.[1]
When Dosage Adjustments Happen
Adjustments are rare and indication-specific:
- Reduce to 150 mg every 4 weeks for psoriasis patients with excellent response after 12 weeks to minimize exposure.
- Lower to 75 mg every 4 weeks for non-radiographic axial spondyloarthritis or enthesitis-related arthritis in children weighing under 50 kg.
- Increase to 300 mg every 2 weeks for enthesitis-related arthritis in children over 50 kg if response is inadequate.[1][2]
No adjustments for renal or mild liver impairment; use caution or avoid in severe cases.
Factors Triggering Changes
Clinicians adjust based on:
- Clinical response (e.g., PASI score improvement in psoriasis).
- Body weight in pediatric patients.
- Tolerability or loss of efficacy, sometimes switching to every 2 weeks temporarily.
Therapeutic drug monitoring isn't standard, but low serum levels may prompt dose increases in non-responders.[3]
Pediatric vs Adult Differences
Pediatric dosing (ages 2+) for juvenile psoriatic arthritis or enthesitis-related arthritis uses 75 mg (under 50 kg) or 150-300 mg (over 50 kg) at similar intervals, scaled by weight more than adults. No frequent tweaks unless efficacy wanes.[1]
What If Response Fails?
For inadequate response after 12-16 weeks, guidelines recommend dose escalation (e.g., 300 mg every 2 weeks), switching biologics, or adding conventional therapy. No universal frequency—decisions are individualized via monitoring.[2][3]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: DrugPatentWatch.com - Cosentyx Patent and Dosing Insights